SK Chemicals285130.KS

About SK Chemicals

SK Chemicals operates two distinct businesses under one roof: green materials and pharmaceuticals. The materials arm produces copolyester resins, a BPA-free alternative to conventional plastics used in cosmetics packaging and household goods, and has pushed into chemically recycled plastics. The life-science arm develops and sells pharmaceutical products, and the company is the controlling shareholder of vaccine maker SK Bioscience. SK Chemicals sits within SK Discovery, a holding structure separate from the main SK Inc. lineage of the wider SK Group. Earnings blend specialty-chemical margins with pharmaceutical income and consolidated vaccine results.

The controlling stake in listed subsidiary SK Bioscience is central to how foreign investors value the shares, creating a holding-company dynamic in which the parent often trades below the appraised worth of its parts. Copolyester demand links the company to global consumer-packaging trends and to regulatory momentum against conventional plastics, a structural tailwind that also invites competition. Its position within SK Discovery, rather than under the main SK holding company, matters for governance analysis. Currency movements affect the materials business, which exports a meaningful share of its output.

The company began in 1969 as Sunkyong Fibers, a polyester producer that anchored the early manufacturing ambitions of the Sunkyong group, later SK. It adopted the SK Chemicals name in 1998 as it shifted from textiles toward specialty chemicals and life science, and in 1999 it won approval for Sunpla, recognized as South Korea's first domestically developed new drug. A December 2017 reorganization divided the old company into SK Discovery, a holding entity, and today's operating SK Chemicals, which relisted in early 2018. The vaccine unit was carved out separately in 2018 to create SK Bioscience.

Revenue rests on two engines with different mechanics. The green-materials arm sells copolyester resins under brands such as ECOZEN and SKYGREEN, earning specialty margins from customers in cosmetics packaging, consumer goods, and appliances who pay up for clarity, durability, and BPA-free credentials; recycled-content grades extend that franchise. The pharmaceutical arm generates product sales from its own portfolio, including patch-based pain treatments and circulation-improvement drugs, plus consolidated results from SK Bioscience. Competitive position in copolyester is unusually strong because only a handful of producers worldwide master the chemistry, while the pharma unit competes in crowded domestic therapeutic markets.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on SK Chemicals →